HK1204943A1 - Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and a gabapentinoid (1r4r)-6--nn--4--49--3h-[-1 1-[34b]]-4- - Google Patents

Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and a gabapentinoid (1r4r)-6--nn--4--49--3h-[-1 1-[34b]]-4-

Info

Publication number
HK1204943A1
HK1204943A1 HK15105574.6A HK15105574A HK1204943A1 HK 1204943 A1 HK1204943 A1 HK 1204943A1 HK 15105574 A HK15105574 A HK 15105574A HK 1204943 A1 HK1204943 A1 HK 1204943A1
Authority
HK
Hong Kong
Prior art keywords
gabapentinoid
pyrano
indol
spiro
dihydro
Prior art date
Application number
HK15105574.6A
Other languages
English (en)
Chinese (zh)
Inventor
Stefanie Frosch
Klaus Linz
Thomas Christoph
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of HK1204943A1 publication Critical patent/HK1204943A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15105574.6A 2012-05-18 2015-06-11 Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and a gabapentinoid (1r4r)-6--nn--4--49--3h-[-1 1-[34b]]-4- HK1204943A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12003940 2012-05-18
PCT/EP2013/001465 WO2013170966A1 (fr) 2012-05-18 2013-05-16 Composition pharmaceutique comprenant de la (1r,4r)-6'-fluoro-n,n-diméthyl-4-phényl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine et un gabapentinoïde

Publications (1)

Publication Number Publication Date
HK1204943A1 true HK1204943A1 (en) 2015-12-11

Family

ID=48539081

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105574.6A HK1204943A1 (en) 2012-05-18 2015-06-11 Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and a gabapentinoid (1r4r)-6--nn--4--49--3h-[-1 1-[34b]]-4-

Country Status (23)

Country Link
US (2) US9320725B2 (fr)
EP (1) EP2849748B1 (fr)
JP (1) JP6116673B2 (fr)
CN (1) CN104284658A (fr)
AU (1) AU2013262072B2 (fr)
BR (1) BR112014028574A2 (fr)
CA (1) CA2873624A1 (fr)
CY (1) CY1119777T1 (fr)
DK (1) DK2849748T3 (fr)
EA (1) EA029766B1 (fr)
ES (1) ES2658218T3 (fr)
HK (1) HK1204943A1 (fr)
HR (1) HRP20171708T1 (fr)
HU (1) HUE034659T2 (fr)
IL (1) IL235658A (fr)
LT (1) LT2849748T (fr)
MX (1) MX356245B (fr)
NO (1) NO2849748T3 (fr)
PL (1) PL2849748T3 (fr)
PT (1) PT2849748T (fr)
RS (1) RS56799B1 (fr)
SI (1) SI2849748T1 (fr)
WO (1) WO2013170966A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
JP6673924B2 (ja) 2015-01-23 2020-03-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US20030056896A1 (en) 1995-05-12 2003-03-27 Frank Jao Effective therapy for epilepsies
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE60325888D1 (de) 2002-11-26 2009-03-05 Alexza Pharmaceuticals Inc Verwendung von loxapine für die herstellung eines mittels zur behandlung von schmerz
US20040222123A1 (en) 2003-05-06 2004-11-11 Barr Laboratories, Inc. Kit for pharmaceuticals
CN1245379C (zh) 2003-10-30 2006-03-15 曹桂东 加巴喷丁的制法
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
GB0412878D0 (en) 2004-06-09 2004-07-14 Pfizer Ltd Use
BRPI0511941A (pt) 2004-06-09 2008-01-22 Pfizer uso de (s, s)-reboxetina ou reboxetina racêmica
US8093408B2 (en) 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US20080014264A1 (en) 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
JP2008106028A (ja) 2006-10-26 2008-05-08 Boehringer Ingelheim Internatl Gmbh 慢性疼痛の治療におけるフリバンセリンの使用
US20080153874A1 (en) 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
WO2008108639A1 (fr) 2007-03-08 2008-09-12 Avantium Holding B.V. Formes co-cristallines de carbamazépine
EP1977744A1 (fr) 2007-04-03 2008-10-08 Chemo Ibérica, S.A. Forme polymorphe alpha de la (S)-prégabaline et son procédé de préparation
PL2244703T3 (pl) 2007-12-21 2012-05-31 Horizon Pharma Ag Lekarstwo, jego wytwarzanie i zastosowanie w leczeniu bolesnych neuropatii
EP2123626A1 (fr) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-cristaux de duloxétine et générateurs de co-cristaux pour le traitement de la douleur
US20090298947A1 (en) 2008-05-28 2009-12-03 Pliva Hrvatska D.O.O. Polymorphic and amorphous forms of lacosamide and amorphous compositions
CA2735857C (fr) 2008-09-05 2019-05-28 Petra Bloms-Funke Composition pharmaceutique de 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol et un antiepileptique
DE102009013613A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
WO2012015027A1 (fr) * 2010-07-30 2012-02-02 東レ株式会社 Agent thérapeutique ou prophylactique pour douleur neuropathique
MX2013000980A (es) * 2010-08-04 2013-02-15 Gruenenthal Gmbh Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n, n-dimetil-)-4-fenil-4', 9'-dihidro-3'h-espiro [ciclohexan-1, 1'-pirano[3, 4, b]indol]-4-amina.
PL2600851T3 (pl) * 2010-08-04 2018-08-31 Grünenthal GmbH Farmaceutyczna forma dozowania zawierająca 6’-fluoro-(n-metylo- lub n,n-dimetyl-o)-4-fenylo-4’,9’-dihydro-3’h-spiro[cykloheksano-1,1’-pirano[3,4,b]indolo]-4-aminę przeznaczona do leczenia bólu neuropatycznego
HUE028436T2 (hu) * 2010-08-04 2016-12-28 Gruenenthal Gmbh Gyógyszerészeti adagolási forma, amely tartalmaz-6'-fluor-(N-metil- vagy N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-spiro[ciklohexán-1,1'-pirano[3,4B]indol]-4-amint
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid

Also Published As

Publication number Publication date
US9629825B2 (en) 2017-04-25
HRP20171708T1 (hr) 2017-12-29
LT2849748T (lt) 2018-01-25
ES2658218T3 (es) 2018-03-08
JP2015516446A (ja) 2015-06-11
EP2849748B1 (fr) 2017-11-01
AU2013262072B2 (en) 2018-01-18
DK2849748T3 (en) 2017-12-04
PT2849748T (pt) 2018-02-07
EA029766B1 (ru) 2018-05-31
IL235658A0 (en) 2015-01-29
JP6116673B2 (ja) 2017-04-19
EA201401268A1 (ru) 2015-06-30
CA2873624A1 (fr) 2013-11-21
HUE034659T2 (en) 2018-02-28
BR112014028574A2 (pt) 2017-06-27
EP2849748A1 (fr) 2015-03-25
AU2013262072A1 (en) 2015-01-22
US20130310434A1 (en) 2013-11-21
RS56799B1 (sr) 2018-04-30
SI2849748T1 (en) 2018-02-28
CN104284658A (zh) 2015-01-14
NO2849748T3 (fr) 2018-03-31
IL235658A (en) 2017-07-31
US20160193183A1 (en) 2016-07-07
WO2013170966A1 (fr) 2013-11-21
MX356245B (es) 2018-05-21
US9320725B2 (en) 2016-04-26
CY1119777T1 (el) 2018-06-27
MX2014012764A (es) 2014-11-21
PL2849748T3 (pl) 2018-03-30

Similar Documents

Publication Publication Date Title
IL235767A (en) Preserved pyrolidines, pharmaceuticals containing them and their uses
HK1183610A1 (en) PHARMACEUTICAL DOSAGE FORM COMPRISING 6-FLUORO-(N-METHYL- OR N,N-DIMETHYL- g )-4-PHENYL-4,9-DIHYDRO-3H-SPIRO[CYCLOHEXANE-1,1-PYRANO[3,4,B]INDOL]-4- AMINE 6--(N-- NN-)-4--49--3H-[-11- [34B]]-4-
HK1183612A1 (en) Pharmaceutical dosage form comprising 6-fluoro-(n-methyl- or n,n-dimethyl- )-4-phenyl-4,9-dihydro-3h-spiro[cylohexane-1,1-pyrano[3,4,b]indol]-4- amine 6--(n-- nn-)-4--49--3h-[-11- [34b]]-4-
HK1204992A1 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
HK1204937A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and an anticonvulsant (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
HK1204942A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano- [3,4,b]indol]-4-amine and a propionic acid derivative (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
HK1204615A1 (en) (1r,4r)7-oxo-2-azabicyclo[2.2.2]oct-5-ene and derivatives thereof (1r4r)7--2-[222]-5-
HK1204943A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and a gabapentinoid (1r4r)-6--nn--4--49--3h-[-1 1-[34b]]-4-
HK1204938A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and a nsar (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4- nsar
HK1199258A1 (zh) '- '- '- '-氟代- -二甲基- -苯基- '， '-二氫- -螺環- 環己烷- '-吡喃並 吲哚基 -鹽酸胺的固體形式
EP2851074A4 (fr) Composition pharmaceutique analgésique
HK1204944A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and antidepressants (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
HK1204939A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and an oxicam (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
HK1204941A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro [cyclohexane-1,1-pyrano- [3,4,b]indol]-4-amine and a salicylic acid component (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
HK1204940A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1- pyrano[3,4,b]indol]-4-amine and paracetamol or propacetamol (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
HK1199218A1 (en) (1r,4r)-6-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4,9- dihydro-3h-spiro-[cyclohexane-1,1-pyrano[3,4,b]indol]-4-amine for treating fibromyalgia and chronic fatigue syndrome (1r,4r)-6--(n-- n,n- -)-4--4,9--3h--[-1,1-[3,4,b] ]-4-
BR112014028557A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n ,n-dimetil-4-fenil-4 ,9-di-hidro-3h-espiro[ciclohexano-1 ,1-pirano-[3,4,b]indol]-4- amina e um anticonvulsivo

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220513